Book contents
- Common Pitfalls in Cognitive and Behavioral Neurology
- Common Pitfalls in Cognitive and Behavioral Neurology
- Copyright page
- Dedication
- Contents
- Diseases Discussed in the Book
- Preface
- Acknowledgements
- Abbreviations
- Part 1 Missing the Diagnosis Altogether
- Part 2 Misidentifying the Impaired Cognitive Domain
- Part 3 Missing Important Clues in the History
- Part 4 Failure of Pattern Recognition
- Part 5 Difficult-to-Characterize Cognitive/Behavioral Disorders
- Part 6 Clinical Findings That Are Subtle
- Part 7 Misinterpreting Test Results
- Part 8 Attributing Findings to a Known or Suspected Disorder
- Part 9 Missing Radiographic Clues
- Part 10 Management Misadventures
- Case 46 I Don’t Know When to Stop
- Case 47 Is It Still Helping?
- Case 48 Caring for the Caregiver
- Case 49 Better Safe than Sorry?
- Case 50 Great Expectations
- Case 51 Nothing Can Be Done
- Index
- Plate Section (PDF Only)
- References
Case 47 - Is It Still Helping?
from Part 10 - Management Misadventures
Published online by Cambridge University Press: 03 November 2020
Book contents
- Common Pitfalls in Cognitive and Behavioral Neurology
- Common Pitfalls in Cognitive and Behavioral Neurology
- Copyright page
- Dedication
- Contents
- Diseases Discussed in the Book
- Preface
- Acknowledgements
- Abbreviations
- Part 1 Missing the Diagnosis Altogether
- Part 2 Misidentifying the Impaired Cognitive Domain
- Part 3 Missing Important Clues in the History
- Part 4 Failure of Pattern Recognition
- Part 5 Difficult-to-Characterize Cognitive/Behavioral Disorders
- Part 6 Clinical Findings That Are Subtle
- Part 7 Misinterpreting Test Results
- Part 8 Attributing Findings to a Known or Suspected Disorder
- Part 9 Missing Radiographic Clues
- Part 10 Management Misadventures
- Case 46 I Don’t Know When to Stop
- Case 47 Is It Still Helping?
- Case 48 Caring for the Caregiver
- Case 49 Better Safe than Sorry?
- Case 50 Great Expectations
- Case 51 Nothing Can Be Done
- Index
- Plate Section (PDF Only)
- References
Summary
This 76-year-old man returned to the clinic, brought by his daughter for monitoring of his progressive memory impairment. Five years previously, neuropsychological evaluation revealed memory encoding deficits and brain MRI showed asymmetric hippocampal atrophy. With a diagnosis of probable Alzheimer disease, he was started on rivastigmine, gradually increased to a dose of 6 mg BID. The family noticed better thinking and less forgetfulness for six months, but he continued to decline thereafter. He went on to have difficulty dressing and bathing and experienced delusions of theft. After five years of treatment with rivastigmine, his daughter wondered if it should be discontinued.
- Type
- Chapter
- Information
- Common Pitfalls in Cognitive and Behavioral NeurologyA Case-Based Approach, pp. 153 - 154Publisher: Cambridge University PressPrint publication year: 2020
References
Daiello, L. A. et al. 2009. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 7(2) 74–83.CrossRefGoogle Scholar
Doody, R. S. et al. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58(3) 427–433.CrossRefGoogle ScholarPubMed
Ferris, S. H. and Farlow, M. 2013. Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors. Clin Interv Aging 8 1007–1014.CrossRefGoogle ScholarPubMed
Howard, R. et al. 2012. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366(10) 893–903.CrossRefGoogle ScholarPubMed
Lanctôt, K. et al. 2015. Predictors of worsening following cholinesterase inhibitor discontinuation trial in institutionalized persons with moderate to severe Alzheimer’s disease: results of a double-blind, placebo controlled trial. Alzheimer’s Dementia 11(7) P520.CrossRefGoogle Scholar
Pariente, A. et al. 2012. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology 78(13) 957–963.CrossRefGoogle ScholarPubMed
Scarpini, E. et al. 2011. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer’s disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis 26(2) 211–220.CrossRefGoogle ScholarPubMed